- Beta Blockers
- ACE Inhibitors
- Angiotensin Receptor Blockers
- Diuretics
- Inotropic Agents
- Aldosterone Antagonist
- Calcium Channel Blockers
- Others
Congestive Heart Failure Treatment market size was valued at USD 19.5 billion in 2022. It is expected to reach a value of USD 31.72 billion by 2029, growing with a CAGR of 7.2% from 2023-29. At present, the treatment of congestive heart failure relies on a range of medications, including angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Additionally, various other therapeutic approaches are employed, such as aldosterone antagonists, amiodarone, antiplatelet agents, anticoagulants, calcium channel blockers, diuretics, and nitrates, among others, to address the needs of patients with heart failure. Congestive heart failure is a chronic and progressive condition that affects the pumping capacity of heart muscles and also referred as heart failure. Congestive heart failure can refer to the stage in which fluid builds up around the heart and causes it to pump inefficiently. Ventricles pump blood to your body's organs and tissues, and the atria receive blood from your body as it circulates back from the rest of your body. Congestive heart failure develops when ventricles unable to pump sufficient volume of blood to the body. Eventually, blood and other fluids can back up inside your lungs, liver, abdomen, and lower body. There are two types of congestive heart failure, they are systolic heart failure and diastolic heart failure. Many generic manufacturers foray into the congestive heart failure treatment market due to patent expirations of CHF innovators drugs. The presence generics expected to hinder the market revenue and may hamper the uptake of new and expected novel drugs. Increase in prevalence of cardiovascular diseases across regions is one the major factors expected to drive the revenue growth of congestive heart failure treatment globally. Lifestyle related factors are expected to add to growing disease incidence of CVDs. In addition growing number of obese patients are expected to bolster the congestive heart failure treatment market. Congestive heart failure is a common condition, especially among older adults. In the United States, it's estimated that around 6.2 million adults have heart failure.
The Congestive Heart Failure Treatment marketKey Developments:
- In July 2015, U.S. Food and Drug Administration (FDA) approved Novartis, Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, to treat heart failure patients with reduced ejection fraction.
- In April 2015, Amgen received U.S. FDA approval for its Corlanor (ivabradine) to treat of heart failure conditions.
Global Congestive Heart Failure Treatment Market Summary
Study Period
2023-29
Base Year
2022
CAGR
7.2%
Largest Market
North America
Fastest Growing Market
Europe
Congestive Heart Failure Treatment Market Dynamics
Congestive heart failure treatment market is expected to show significant growth in demand over the forecast period owing to rising incidences of cardiovascular diseases. Congestive heart failure is one of the most common medical conditions that is responsible for the death of people globally. According to WHO, around 6.5 million of people are diagnosed with congestive heart failure every year and around 2% of global population are hospitalized due to congestive heart failure. In July, 2015, Novartis launched novel combination drug Entresto (LCZ-696) a novel branded CHF drug. The prescription of mineralocorticoid receptor antagonists (MRAs), such as spironolactone, due to their efficiency in heart failure treatment is expected to increase the Congestive heart failure (CHF) treatment markets during the forecast period.
North-America Got Significant Share
Congestive Heart Failure Treatment Market Regional Analysis
Geographically global market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and European markets are significantly having high growth potential for congestive heart failure treatment due to the increase in incidences of heart failures in these regions. According to American Heart Association, Heart Disease and Stroke Statistics 2017, congestive heart failure occupies 8.5% of heart diseases in US. merging markets like Asia Pacific and Latin America are set to witness significant growth in this industry due to change in demographics, healthcare reforms, healthcare expenditure, and an increase in treatment for congestive heart failure conditions.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The Congestive Heart Failure Treatment Market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Congestive Heart Failure Treatment Market Segmentation
By Drug Class
By Route-Administration
- Oral
- Intravenous
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
Due to the COVID-19 pandemic, the global Congestive Heart Failure (CHF) Treatment market size was valued at USD 19.5 billion in 2022, with a CAGR of 7.2Percent during the review period.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
Numerous pharmaceutical companies produce medications used in the treatment of congestive heart failure (CHF). Some of the prominent pharmaceutical companies involved in the development and distribution of medications for CHF include. AstraZeneca plc. (UK), Bristol-Myers Squibb Co. (U.S), GlaxoSmithKline plc (GSK) (UK), Merck & Co. Inc. (U.S), Mylan Inc. (U.S), Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), Valeant Pharmaceuticals International Inc. (Canada)
| 1.Executive Summary |
| 2.Global Congestive Heart Failure Treatment Market Introduction |
| 2.1.Global Congestive Heart Failure Treatment Market - Taxonomy |
| 2.2.Global Congestive Heart Failure Treatment Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Route-Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Congestive Heart Failure Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Congestive Heart Failure Treatment Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Congestive Heart Failure Treatment Market By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Beta Blockers |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. ACE Inhibitors |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Angiotensin Receptor Blockers |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Diuretics |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Inotropic Agents |
| 5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Aldosterone Antagonist |
| 5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Calcium Channel Blockers |
| 5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Others |
| 5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 6.Global Congestive Heart Failure Treatment Market By Route-Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Intravenous |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Congestive Heart Failure Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Congestive Heart Failure Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Congestive Heart Failure Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Beta Blockers |
| 9.1.2.ACE Inhibitors |
| 9.1.3.Angiotensin Receptor Blockers |
| 9.1.4.Diuretics |
| 9.1.5.Inotropic Agents |
| 9.1.6.Aldosterone Antagonist |
| 9.1.7.Calcium Channel Blockers |
| 9.1.8.Others |
| 9.2. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Intravenous |
| 9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Online Pharmacies |
| 9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Congestive Heart Failure Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Beta Blockers |
| 10.1.2.ACE Inhibitors |
| 10.1.3.Angiotensin Receptor Blockers |
| 10.1.4.Diuretics |
| 10.1.5.Inotropic Agents |
| 10.1.6.Aldosterone Antagonist |
| 10.1.7.Calcium Channel Blockers |
| 10.1.8.Others |
| 10.2. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Intravenous |
| 10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Online Pharmacies |
| 10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Congestive Heart Failure Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Beta Blockers |
| 11.1.2.ACE Inhibitors |
| 11.1.3.Angiotensin Receptor Blockers |
| 11.1.4.Diuretics |
| 11.1.5.Inotropic Agents |
| 11.1.6.Aldosterone Antagonist |
| 11.1.7.Calcium Channel Blockers |
| 11.1.8.Others |
| 11.2. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Intravenous |
| 11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Online Pharmacies |
| 11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Congestive Heart Failure Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Beta Blockers |
| 12.1.2.ACE Inhibitors |
| 12.1.3.Angiotensin Receptor Blockers |
| 12.1.4.Diuretics |
| 12.1.5.Inotropic Agents |
| 12.1.6.Aldosterone Antagonist |
| 12.1.7.Calcium Channel Blockers |
| 12.1.8.Others |
| 12.2. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Intravenous |
| 12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Online Pharmacies |
| 12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Congestive Heart Failure Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Beta Blockers |
| 13.1.2.ACE Inhibitors |
| 13.1.3.Angiotensin Receptor Blockers |
| 13.1.4.Diuretics |
| 13.1.5.Inotropic Agents |
| 13.1.6.Aldosterone Antagonist |
| 13.1.7.Calcium Channel Blockers |
| 13.1.8.Others |
| 13.2. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Intravenous |
| 13.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Online Pharmacies |
| 13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.AstraZeneca plc. (UK) |
| 14.2.2.Bristol-Myers Squibb Co. (U.S), |
| 14.2.3.GlaxoSmithKline plc (GSK) (UK) |
| 14.2.4.Merck & Co. Inc. (U.S) |
| 14.2.5.Mylan Inc. (U.S) |
| 14.2.6.Novartis AG (Switzerland) |
| 14.2.7.Pfizer Inc. (U.S) |
| 14.2.8.Sanofi (France) |
| 14.2.9.Valeant Pharmaceuticals International Inc. (Canada) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- AstraZeneca plc. (UK)
- Bristol-Myers Squibb Co. (U.S),
- GlaxoSmithKline plc (GSK) (UK)
- Merck & Co. Inc. (U.S)
- Mylan Inc. (U.S)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S)
- Sanofi (France)
- Valeant Pharmaceuticals International Inc. (Canada)